Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hypertension

  Free Subscription

Articles published in
Lancet
    September 2017
  1. SPIERING W, Williams B, Van der Heyden J, van Kleef M, et al
    Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.
    Lancet. 2017 Sep 1. pii: S0140-6736(17)32337.
    >> Share

  2. COURAND PY, Lantelme P
    Stretching the carotid sinus to treat resistant hypertension.
    Lancet. 2017 Sep 1. pii: S0140-6736(17)32298.
    >> Share

    August 2017
  3. AZIZI M
    Catheter-based renal denervation for treatment of hypertension.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32293.
    >> Share

  4. TOWNSEND RR, Mahfoud F, Kandzari DE, Kario K, et al
    Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32281.
    >> Share

    July 2017
  5. RODGERS A, Chow CK, Thakkar J, Bennett A, et al
    A personalised or procrustean approach to treating hypertension? - Authors' reply.
    Lancet. 2017;390:27-28.
    >> Share

  6. GABB GM, Mol PGM, Arnolda LF
    A personalised or procrustean approach to treating hypertension?
    Lancet. 2017;390:26-27.
    >> Share

    June 2017
  7. MUNDLE S, Bracken H, Khedikar V, Mulik J, et al
    Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.
    Lancet. 2017 Jun 28. pii: S0140-6736(17)31367.
    >> Share

  8. SURI V, Sikka P
    Oral misoprostol for induction of labour in hypertensive pregnancies.
    Lancet. 2017 Jun 28. pii: S0140-6736(17)31453.
    >> Share

    March 2017
  9. LUYCKX VA, Perico N, Somaschini M, Manfellotto D, et al
    A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group.
    Lancet. 2017 Mar 8. pii: S0140-6736(17)30576.
    >> Share

    February 2017
  10. GRADMAN AH
    A quarter-dose quadpill for initial treatment of hypertension.
    Lancet. 2017 Feb 9. pii: S0140-6736(17)30331.
    >> Share

  11. CHOW CK, Thakkar J, Bennett A, Hillis G, et al
    Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
    Lancet. 2017 Feb 9. pii: S0140-6736(17)30260.
    >> Share

    January 2017
  12. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    >> Share

  13. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    >> Share

  14. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    >> Share

  15. ZENG X, Deng A, Ding Y
    The INTERSTROKE study on risk factors for stroke.
    Lancet. 2017;389:35.
    >> Share

    December 2016
  16. SLIWA K
    The heart of Africa: succeeding against the odds.
    Lancet. 2016;388:e28-e36.
    >> Share

    October 2016
  17. SCHOFIELD G, Henderson G, Crofts C
    Beyond salt-where next for hypertension epidemiology?
    Lancet. 2016;388:2110-2111.
    >> Share

  18. MENTE A, O'Donnell MJ, Yusuf S
    Sodium and cardiovascular disease - Authors' reply.
    Lancet. 2016;388:2113-2114.
    >> Share

  19. CAPPUCCIO FP
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112.
    >> Share

  20. KATZ J
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2112-2113.
    >> Share

  21. STRAZZULLO P, Giampaoli S, Iacoviello L, Rossi L, et al
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111.
    >> Share

  22. WALD N, Law M
    Sodium and cardiovascular disease.
    Lancet. 2016;388:2111-2112.
    >> Share

  23. ALDERMAN MH
    Dietary sodium: paradigm shifts from public health to clinical medicine.
    Lancet. 2016;388:2110.
    >> Share


  24. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
    Lancet. 2016;388:1659-1724.
    >> Share

    September 2016
  25. WATTS G
    Neil Poulter: upping the pressure on hypertension.
    Lancet. 2016 Sep 29. pii: S0140-6736(16)31775.
    >> Share

  26. OLSEN MH, Angell SY, Asma S, Boutouyrie P, et al
    A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension.
    Lancet. 2016 Sep 22. pii: S0140-6736(16)31134.
    >> Share

    August 2016
  27. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    >> Share

  28. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    >> Share

  29. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    >> Share

    July 2016
  30. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    >> Share

  31. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    >> Share

  32. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  33. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    >> Share

  34. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

    June 2016
  35. SONODA Y, Higuchi A, Morita T, Mori J, et al
    Intensive blood pressure lowering.
    Lancet. 2016;387:2291.
    >> Share

  36. XIE X, Atkins E, Lv J, Rodgers A, et al
    Intensive blood pressure lowering - Authors' reply.
    Lancet. 2016;387:2291.
    >> Share

    May 2016
  37. OK E, Asci G, Chazot C, Ozkahya M, et al
    Controversies and problems of volume control and hypertension in haemodialysis.
    Lancet. 2016 May 20. pii: S0140-6736(16)30389.
    >> Share

  38. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    >> Share

    April 2016
  39. WILLIAMS B, MacDonald TM, Morant SV, Brown MJ, et al
    PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
    Lancet. 2016;387:1373-4.
    >> Share

  40. DALE A, Hartley P, Goldacre B
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1372-3.
    >> Share

  41. GKALIAGKOUSI E, Gavriilaki E, Triantafyllou A, Douma S, et al
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1372.
    >> Share

  42. BOUTARI C, Stavropoulos K, Imprialos K, Doumas M, et al
    PATHWAY-2: spironolactone for resistant hypertension.
    Lancet. 2016;387:1371-2.
    >> Share

  43. ZALCMAN G, Mazieres J, Margery J, Greillier L, et al
    Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Lancet. 2016;387:1405-14.
    >> Share

    March 2016
  44. LAURENT S, Boutouyrie P
    Blood pressure lowering trials: wrapping up the topic?
    Lancet. 2016;387:923-4.
    >> Share

    February 2016
  45. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
    Lancet. 2016 Feb 5. pii: S0140-6736(16)00002.
    >> Share

    January 2016
  46. BRUNSTROM M, Carlberg B
    Lower blood pressure targets: to whom do they apply?
    Lancet. 2016;387:405-6.
    >> Share

    December 2015
  47. ETTEHAD D, Emdin CA, Kiran A, Anderson SG, et al
    Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
    Lancet. 2015 Dec 23. pii: S0140-6736(15)01225.
    >> Share


  48. Health security: the defining challenge of 2016.
    Lancet. 2015;386:2445.
    >> Share

    November 2015
  49. LOBO MD, Sobotka PA, Dolan E, Witkowski A, et al
    Central arteriovenous anastomosis and hypertension - Authors' reply.
    Lancet. 2015;386:1821-2.
    >> Share

  50. DEINUM J, Wetzels JF
    Central arteriovenous anastomosis and hypertension.
    Lancet. 2015;386:1821.
    >> Share

  51. XIE X, Atkins E, Lv J, Bennett A, et al
    Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
    Lancet. 2015 Nov 7. pii: S0140-6736(15)00805.
    >> Share

    October 2015
  52. BROEKHUIJSEN K, Groen H, van den Berg PP, Mol BW, et al
    Gestational hypertension and advanced maternal age - Authors' reply.
    Lancet. 2015;386:1628.
    >> Share

  53. DIETL A, Farthmann J
    Gestational hypertension and advanced maternal age.
    Lancet. 2015;386:1627-8.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016